Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium.
The characterization and localization of endothelin A (ETA) and endothelin B (ETB) receptors have been determined in tissue sections of the human atrioventricular conducting system, surrounding regions of atrial and ventricular myocardium, and the left ventricular free wall by use of radioligand binding, polymerase chain reaction, and in situ hybridization. Selective ETA (BQ123) and ETB (BQ3020) compounds in conjunction with [125I]endothelin-1 revealed the presence of ETA and ETB receptors in the left ventricular free wall (BQ123: 57 +/- 5% ETA, 43 +/- 2% ETB, n = 3; BQ3020: 67 +/- 3% ETA, 33 +/- 3% ETB, n = 3). Autoradiography using [125I]endothelin-1 in the absence or presence of BQ3020, BQ123, or endothelin-1 showed ETA and ETB receptors localized to atrial and ventricular myocardium, the atrioventricular conducting system, and endocardial cells. There was a higher proportion of ETB receptors in the atrioventricular node and the penetrating and branching bundles of His than in the surrounding interventricular and interatrial septa (p < 0.0001). There was a lower density of ETB receptors in the interventricular septum compared with the interatrial septum and the atrioventricular conducting system (p = 0.009) and a lower density of ETA receptors in the atrioventricular conducting system compared with interatrial and interventricular septa (p = 0.008). Isolated right atrial myocytes showed a higher proportion of ETA receptors (91 +/- 12%, n = 3). Amplification of left ventricular free wall cDNA by polymerase chain reaction revealed the presence of ETA and ETB receptor mRNA. mRNA for both subtypes was detected in isolated atrial myocytes. In situ hybridization showed ETA and ETB receptor mRNA localization to atrial and ventricular myocardium, the atrioventricular conducting system, and endocardial cells. These studies demonstrate the presence of ETA and ETB receptors in human myocardium and the atrioventricular conducting system.
Molenaar
P
P
Department of Obstetrics and Gynaecology, Addenbrooke's Hospital, Cambridge, UK.
O'Reilly
G
G
Sharkey
A
A
Kuc
R E
RE
Harding
D P
DP
Plumpton
C
C
Gresham
G A
GA
Davenport
A P
AP
D000595:Amino Acid Sequence; D001483:Base Sequence; D002036:Bundle of His / Q000737:chemistry*; D004699:Endocardium / Q000737:chemistry; D016232:Endothelins / Q000494:pharmacology; D006325:Heart Atria / Q000737:chemistry; D006329:Heart Conduction System / Q000737:chemistry*; D006352:Heart Ventricles; D006801:Humans; D008969:Molecular Sequence Data; D009206:Myocardium / Q000737:chemistry*; D010446:Peptide Fragments / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D012313:RNA / Q000032:analysis; D017466:Receptors, Endothelin / Q000032:analysis* / Q000187:drug effects
D016232:Endothelins; D010446:Peptide Fragments; D010456:Peptides, Cyclic; D017466:Receptors, Endothelin; C075771:BQ 3020; D012313:RNA; C072247:cyclo(Trp-Asp-Pro-Val-Leu)